Navigation Links
Celsion Completes Enrollment in Phase I Liver Cancer Study

COLUMBIA, Md.--(BUSINESS WIRE)--May 30, 2007 - CELSION CORPORATION (AMEX:CLN) today announced the completion of its Phase I dose escalation study, using ThermoDox(R), to treat non-resectable liver cancer. The study which was conducted under a Cooperative Research and Development Agreement (CRADA) was performed at the National Cancer Institute (NCI) of the National Institutes of Health, under the leadership of Dr. Steven K. Libutti, Senior Investigator, Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, NCI and Dr. Bradford J. Wood, Chief, Interventional Radiology Research at the National Institutes of Health Clinical Center and at Queen Mary Hospital in Hong Kong under the leadership of Dr. Ronnie T. P. Poon, MD, Professor of Surgery, Faculty of Medicine at Queen Mary Hospital, University of Hong Kong.

In the study, a total of 24 primary and metastatic liver cancer patients, with up to 4 lesions ranging from 3 to 7 centimeters, were treated with ThermoDox in combination with radiofrequency ablation at doses ranging from 20 to 60 mg/m2. Enrollment in the study has been completed, and clinical data is currently being assembled for analysis and eventual submission for the FDA. While the Phase I study was designed to determine the maximum safe dose and safety profile of ThermoDox, additional analyses will be undertaken to evaluate any clinical effects achieved during the study.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented "Completion of the liver cancer Phase I dosing escalation study represents another milestone in our ThermoDox development program and is consistent with our timelines to initiate our Phase III registrational study for Primary Liver Cancer later this year."

Celsion has licensed the global rights to the temperature-sensitive liposome technology from Duke University where ThermoDox is also being used in a Phase I clinical stu dy of patients with recurrent breast cancer on the chest wall under the care of Dr. Kim Blackwell, the principal investigator.

About Celsion: Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System.

Celsion has also developed a microwave based system, the Prolieve Thermodilatation(R) system, for the treatment of benign prostatic hyperplasia which is marketed in the United States under an exclusive distribution agreement with Boston Scientific Corporation. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

NO ENDORSEMENT OF CELSION CORPORATION OR ANY OF ITS PRODUCTS OR SERVICES BY THE NATIONAL INSTITUTES OF HEALTH OR THE CLINICAL CENTER IS INTENDED OR SHOULD BE INFERRED.

Contact

Celsion Corporation
Tony Deasey, 410-290-5390
tony@celsion.com
or
General Info:
Financial Relations Board
Marilynn Meek, 212-827-3773
mmeek@financialrelationsboard.com
or
Investor Info:
Susan Garland, 212-827-3775
sgarland@financialrelationsboard.com


'"/>




Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... Fla. , Feb. 19, 2017  nThrive™, ... revenue cycle portfolio and thought leadership at the ... receiving a category leader award from KLAS. ... panel discussion focused on how market trends shape ... -  particularly a sophisticated, comprehensive Patient Access solution. ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue ... the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):